Natera announces new data on MRD test to be presented at ASCO GI 2023

Natera announced that new data on its personalized and tumor-informed molecular residual disease, MRD, test, Signatera, will be presented at the American Society of Clinical Oncology’s 2023 Gastrointestinal Cancers Symposium, ASCO GI, taking place January 19 – 21, 2023 in San Francisco, California. The presentations will highlight findings on the utility of Signatera for MRD assessment in colorectal, esophageal, gastric and anal cancers, in a total of five presentations. "On the heels of the groundbreaking CIRCULATE-Japan results just released, we are excited to share additional data further underscoring the real-world utility of Signatera in GI cancers," said Solomon Moshkevich, general manager of oncology at Natera. "This data continues to reinforce the value of personalized and tumor-informed MRD testing across different treatment settings." The preliminary findings from this study suggest that though cfDNA concentration is significantly increased in the first 2-4 weeks, Signatera detection rates remained consistent with those of weeks 4-8, indicating that standard MRD testing windows could start two weeks after surgery.